VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

CAR-TCR Summit Europe 2021 | CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 alloSHRINK trial (NCT03692429) evaluating CYAD-101, a non-gene edited allogeneic CAR-T cell therapy that targets the natural killer group 2D (NKG2D) receptor, in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Preliminary data in 15 patients with MSS mCRC suggests that CYAD-101 therapy may result in improved clinical responses and progression-free survival, although studies are ongoing and further data is required to confirm the benefits in this patient group. This interview took place during the CAR-TCR Summit Europe 2021.